Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by coalbeton Feb 14, 2019 6:07pm
154 Views
Post# 29367268

July 2018

July 2018Dr. Norman Marcon, MD, FRCP, Professor of Medicine in University
of Toronto, Chief of Gastroenterology for St. Michael's Hospital,
Toronto, Ontario stated, "This research was inspired by Theralase's
research into the role of the human glycoprotein Transferrin ("Tf") and
its associated cellular membrane Transferrin Receptor ("TfR") CD71,
that according to previous Theralase research is responsible for the
targeted uptake of Theralase's lead PDC, TLD-1433, by cancer cells. The
aim of our research was to characterize CD71 expression in human
samples of esophageal carcinomas and their precursor lesions.
Remarkably, moderate to strong CD71 staining was seen almost
universally (97.2%) in both SCC and adenocarcinoma. There was a
significantly stronger expression of CD71 in HGD and carcinomas versus
LGD and normal squamous mucosa tissues (p (0.02). This research is
exciting as we now have a way to distinguish between LGD and HGD
lesions. Moreover, CD71 is an important target for Rutherrin(R)
(TLD-1433 combined with transferrin) and hence the development of an
effective, targeted and highly personalised PDT destruction of HGD
precursor lesions and cancers of the esophagus. This
 
latest research was presented and well received at the annual
Canadian Academy of Pathology Meeting held in Quebec City, Quebec,
Canada from July 7 to 10, 2018. Our therapeutic endoscopy group is
looking forward to continuing our research with Theralase to clinically
evaluate this technology in a Phase Ib clinical study aimed at the
destruction of esophageal cancer."
 

Bullboard Posts